Oxidative stress and macrolides in bronchiectasis - Exhaling few clues

Respirology

Volumn 18, Issue 7, 2013, Pages 1037-1038

  Wong, Conroy ^a   Jones, Stuart ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

anti oxidant; bronchiectasis; exhaled breath condensate; macrolide; oxidative stress

Indexed keywords

8 ISOPROSTANE; ALPHA TOCOPHEROL; AZITHROMYCIN; ERYTHROMYCIN; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROLIDE; NITRATE; NITRITE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROFLUMILAST; SOLITHROMYCIN; TRANSCRIPTION FACTOR AP 1; UBIDECARENONE; UBIQUINONE; ZIDOVUDINE;

ANTIOXIDANT ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BRONCHIECTASIS; EDITORIAL; HUMAN; MICROBIAL COLONIZATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION;

ANTI-OXIDANT; BRONCHIECTASIS; EXHALED BREATH CONDENSATE; MACROLIDE; OXIDATIVE STRESS;

AZITHROMYCIN; BRONCHIECTASIS; FEMALE; HUMANS; MALE; OXIDATIVE STRESS;

EID: 84884847715     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12161     Document Type: Editorial

References (12)

1. Park HS, Kim SR, Lee YC,. Impact of oxidative stress on lung diseases. Respirology 2009; 14: 27-38.
2. Olveira G, Olveira C, Dorado A, et al. Cellular and plasma oxidative stress biomarkers are raised in adults with bronchiectasis. Clin. Nutr. 2013; 32: 112-117.
3. Fuschillo S, De Felice A, Balzano G,. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur. Respir. J. 2008; 31: 396-406.
4. Kanoh S, Rubin BK,. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010; 23: 590-615.
5. de Diego A, Milara J, Martinez E, et al. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respirology 2013; 18.7: 1056-1062.
6. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
7. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-1259.
8. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309: 1260-1267.
9. Davis MD, Montpetit A, Hunt J,. Exhaled breath condensate: an overview. Immunol. Allergy Clin. North Am. 2012; 32: 363-375.
10. Lee W, Thomas PS,. Oxidative stress in COPD and its measurement through exhaled breath condensate. Clin. Transl. Sci. 2009; 2: 150-155.
11. Galli F, Battistoni A, Gambari R, et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim. Biophys. Acta 2012; 1822: 690-713.
12. Wada H, Takizawa H,. Future treatment for COPD: targeting oxidative stress and its related signal. Recent Pat. Inflamm. Allergy Drug Discov. 2013; 7: 1-11.